✦ LIBER ✦

7015 POSTER DISCUSSION Fatigue Improvement/Reduction With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel – Results From the COU-AA-301 Phase 3 Study

✍ Scribed by Sternberg, C.N.; Scher, H.I.; Molina, A.; North, S.; Mainwaring, P.; Hao, Y.; Gagnon, D.; Kheoh, T.; Haqq, C.M.; de Bono, J.

Book ID: 123584305
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 62 KB
Volume: 47
Category: Article
ISSN: 0959-8049
DOI: 10.1016/S0959-8049(11)71966-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

7001 ORAL Abiraterone Acetate Improves F

7001 ORAL Abiraterone Acetate Improves Functional Status in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Post-docetaxel – Results From the COU-AA-301 Phase 3 Study

✍ Harland, S.; de Bono, J.S.; Haqq, C.M.; Staffurth, J.N.; Hao, Y.; Gagnon, D.; Li 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 41 KB

7000 ORAL Final Overall Survival (OS) An

7000 ORAL Final Overall Survival (OS) Analysis of COU-AA-301, a Phase 3 Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Pretreated With Docetaxel

✍ Fizazi, K.; Scher, H.I.; Molina, A.; Logothetis, C.J.; Jones, R.J.; Staffurth, J 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 58 KB

127 Improved survival in elderly (≥75 yr

127 Improved survival in elderly (≥75 yr) metastatic castration-resistant prostate cancer (mCRPC) patients upon treatment with abiraterone acetate (AA) plus prednisone (P) progressing after docetaxel-based chemotherapy: Results from COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study

✍ P.F.A. Mulders; A. Molina; M. Marberger; F. Saad; J.H. Li; T. Kheoh; C.M. Haqq; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 37 KB

705 ABIRATERONE ACETATE PLUS LOW-DOSE PR

705 ABIRATERONE ACETATE PLUS LOW-DOSE PREDNISONE HAS A FAVORABLE SAFETY PROFILE, IMPROVES SURVIVAL AND PRODUCES PSA AND RADIOGRAPHIC RESPONSES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER DOCETAXEL-BASED CHEMOTHERAPY: RESULTS FROM COU-AA-301, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY

✍ Saad, Fred; de Bono, Johann S.; Haqq, Christopher M.; Logothetis, Christopher J. 📂 Article 📅 2011 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 56 KB